Research Topics
Species | FRANK S HODISummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901John D Roberts
Virginia Commonwealth University, Richmond, Virgina 23298 0037, USA
J Immunother 29:95-101. 2006..The combination of g209-2M and low-dose IL-2 is safe and tolerable but inactive against advanced melanoma. Absence of evidence of immunization raises concerns for peptide-based immunization strategies with concurrent IL-2...- Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stageF Stephen Hodi
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Cancer Res 12:673-8. 2006 - Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cellMarcus O Butler
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Clin Cancer Res 13:1857-67. 2007..To overcome this, we sought to establish a clinical grade culture system that can reproducibly generate antigen-specific cytotoxic T lymphocytes (CTL)... - Cytotoxic T-lymphocyte-associated antigen-4F Stephen Hodi
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
Clin Cancer Res 13:5238-42. 2007.... 
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsF Stephen Hodi
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 105:3005-10. 2008....
Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathwaysXinQi Wu
Department of Medical Oncology, Melanoma Disease Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02215, USA
Mol Cancer Ther 11:1905-14. 2012..Targeted PKC inhibition with drugs such as AEB071 offers novel therapeutic potential for uveal melanoma harboring GNAQ mutations...- Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"Paolo A Ascierto
Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
J Transl Med 10:83. 2012.... - Defining the critical hurdles in cancer immunotherapyBernard A Fox
Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
J Transl Med 9:214. 2011..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer... - Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanomaJun Zhou
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Cancer Immunol Immunother 61:655-65. 2012..High frequency immune responses in melanoma patients, associations with favorable treatment outcomes, and its essential role in melanoma pathogenesis support the development of ML-IAP as a disease marker and therapeutic target... - CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNSF Stephen Hodi
Melanoma Program, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Nat Clin Pract Oncol 5:557-61. 2008..MRI of the spine and brain revealed multiple metastases. The patient received ipilimumab and after 3 months experienced intermittent confusion and focal seizures... - Improved survival with ipilimumab in patients with metastatic melanomaF Stephen Hodi
Dana Farber Cancer Institute, Boston, MA 02115, USA
N Engl J Med 363:711-23. 2010.... - Overcoming immunological tolerance to melanoma: Targeting CTLA-4F Stephen Hodi
Dana Farber Cancer Institute, Boston, Massachusetts, USA
Asia Pac J Clin Oncol 6:S16-23. 2010..Effective anti-tumor immunity and serious autoimmunity can be disassociated. Further targeting of anti-tumor T(regs)in combinatorial therapy approaches may be a rich avenue of future investigation... - Withdrawal of immunosuppression contributing to the remission of malignant melanoma: a case reportF Stephen Hodi
Dana-Farber Cancer Institute, Boston, MA 02115, USA
Cancer Immun 5:7. 2005 - Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsF Stephen Hodi
Department of Adult Oncology, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 100:4712-7. 2003..These findings suggest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer patients... - Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunityGerald P Linette
Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston, 02114, USA
Clin Cancer Res 11:7692-9. 2005..CONCLUSION: The high rate of immunization as measured by three independent assays and the occurrence of clinical regression support continued investigation of G280-9V peptide as a candidate epitope in melanoma vaccine formulations... - The biologic importance of tumor-infiltrating lymphocytesF Stephen Hodi
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA, USA
J Cutan Pathol 37:48-53. 2010..These findings show a concordance between the immune signature of tumor protection in endogenous and therapy-induced responses, strongly supporting Martin Mihm's original insights... - Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysisDarryl A Oble
Department of Pathology, Massachusetts General Hospital, Boston, MA 02114 2696, USA
Am J Surg Pathol 32:1130-7. 2008.... - Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccinesMasahisa Jinushi
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA, USA
Immunol Rev 222:287-98. 2008..Together, these results define key regulatory circuits that attenuate immune-mediated tumor destruction and suggest novel combinatorial therapies that might enhance the clinical activity of GM-CSF-secreting tumor cell vaccines... - Hypopigmentation associated with an adenovirus-mediated gp100/MART-1-transduced dendritic cell vaccine for metastatic melanomaHensin Tsao
Department of Dermatology, Massachusetts General Hospital, Boston, MA 02114, USA
Arch Dermatol 138:799-802. 2002..More recent strategies have focused on using antigen-presenting dendritic cells as vaccines... - Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicityMasahisa Jinushi
Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 103:9190-5. 2006..Moreover, these results highlight the therapeutic potential of anti-MICA antibodies to overcome immune suppression and effectuate tumor destruction in patients... - Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanomaRobert Soiffer
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
J Clin Oncol 21:3343-50. 2003..CONCLUSION: Vaccination with irradiated, autologous melanoma cells engineered to secrete GM-CSF by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma... - MUC1-like tandem repeat proteins are broadly immunogenic in cancer patientsJoseph A Mollick
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Cancer Immun 3:3. 2003..These data add to the growing list of tumor antigens that appear to be translated in two frames, and suggest that OGFr and OGFr-ARF may be useful targets for vaccination... - Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study GroupDavid F McDermott
Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, East KS 159, Boston, MA, USA
J Clin Oncol 26:2178-85. 2008..This phase II study evaluated the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma... - Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destructionJan C Schmollinger
Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 100:3398-403. 2003..These findings demonstrate that ML-IAP can serve as a target for immune-mediated tumor destruction, but that antigen-loss variants can accomplish immune escape... - Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancerKaren S Anderson
Cancer Vaccine Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
J Proteome Res 7:1490-9. 2008..Here, we present the first demonstration of the application of programmable protein microarray ELISAs for the rapid identification of breast cancer autoantibodies... - Concerted potent humoral immune responses to autoantigens are associated with tumor destruction and favorable clinical outcomes without autoimmunityTaylor Sittler
University of Massachusetts Medical School, Worcester, Massachusetts, USA
Clin Cancer Res 14:3896-905. 2008..We sought to identify targets of responses from this vaccination strategy... - Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinomaRavi Salgia
Department of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02215, USA
J Clin Oncol 21:624-30. 2003..One mixed response was observed. CONCLUSION: Vaccination with irradiated autologous NSCLC cells engineered to secrete GM-CSF enhances antitumor immunity in some patients with metastatic NSCLC... - Imatinib targeting of KIT-mutant oncoprotein in melanomaXiaofeng Jiang
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Clin Cancer Res 14:7726-32. 2008..Biological effects of KIT inhibition in these melanomas remain poorly understood. We sought to investigate further the effects of imatinib in these melanoma subsets... - Modulation of T-cell activation by malignant melanoma initiating cellsTobias Schatton
Transplantation Research Center, Children s Hospital Boston, Boston, Massachusetts 02115, USA
Cancer Res 70:697-708. 2010..Our findings identify novel T-cell modulatory functions of ABCB5(+) melanoma subpopulations and suggest specific roles for these MMICs in the evasion of antitumor immunity and in cancer immunotherapeutic resistance... - ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destructionF Stephen Hodi
Department of Adult Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 99:6919-24. 2002..Taken together, these findings demonstrate that potent humoral responses to ATP6S1 are associated with immune-mediated destruction of diverse tumors... - Phase II study of paclitaxel and carboplatin for malignant melanomaF Stephen Hodi
Adult Oncology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
Am J Clin Oncol 25:283-6. 2002..Comparisons with other treatment regimens and the search for additional active compounds against melanoma are needed... - Major response to imatinib mesylate in KIT-mutated melanomaF Stephen Hodi
The Melanoma Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
J Clin Oncol 26:2046-51. 2008 - Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREXAngela M Krackhardt
Department of Adult Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Blood 100:2123-31. 2002..These findings demonstrate that humoral and cellular immune responses against CLL-associated antigens can be detected. Ongoing experiments investigate their potential for the development of immunotherapeutic strategies... - Modeling genomic diversity and tumor dependency in malignant melanomaWilliam M Lin
Department of Medical Oncology, Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Cancer Res 68:664-73. 2008..Genetically defined cell culture collections therefore offer a rich framework for systematic functional studies in melanoma and other tumors... - High-throughput oncogene mutation profiling in human cancerRoman K Thomas
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
Nat Genet 39:347-51. 2007..These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention... - Mutation-driven drug development in melanomaKeith T Flaherty
Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
Curr Opin Oncol 22:178-83. 2010..The purpose of this review is to define those oncogenes for which there are preclinical data supporting clinical trials and to summarize results from clinical investigations... - Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer InstituteKenneth A Katz
Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19104, USA
Melanoma Res 15:77-82. 2005..The demographic and survival characteristics of this MUP cohort mirrored those found in previous studies. More studies of MUP patients, as well as a standardized definition of MUP, may shed light on the pathogenesis and prognosis of MUP... - Case records of the Massachusetts General Hospital. Case 2-2007. A 49-year-old woman with a pigmented lesion on the armJohn F Thompson
Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, Australia
N Engl J Med 356:285-92. 2007
Research Grants
- CTLA-4 Blockade in GM-CSF Vaccinated PatientsFRANK HODI; Fiscal Year: 2004..abstract_text> ..
- MELANOMA ANTIGENS INDENTIFIED FROM GMCSF VACCINATIONFRANK HODI; Fiscal Year: 2002..Further identification of immunogenic antigens in melanoma offers promise for future therapies. ..